ARC 13950

Drug Profile

ARC 13950

Alternative Names: FPL 13950

Latest Information Update: 18 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca R&D Charnwood
  • Class Acetamides; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 28 Jan 1999 FPL 13590 is now called ARC 13590
  • 18 Aug 1995 Preclinical development for Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top